Rectal 1% Tenofovir Gel Use Associates with Altered Epidermal Protein Expression

Rectal use of a 1% tenofovir (TFV) gel is currently being evaluated for HIV prevention. While careful assessment of mucosal safety of candidate microbicides is a primary concern, tools to assess mucosal toxicity are limited. Mass spectrometry-based proteomics is a sensitive and high-throughput techn...

Descripción completa

Detalles Bibliográficos
Autores principales: Romas, Laura, Birse, Kenzie, Mayer, Kenneth H., Abou, Max, Westmacott, Garrett, Giguere, Rebecca, Febo, Irma, Cranston, Ross D., Carballo-Diéguez, Alex, McGowan, Ian, Burgener, Adam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mary Ann Liebert, Inc. 2016
Materias:
PReP
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5067863/
https://www.ncbi.nlm.nih.gov/pubmed/27316778
http://dx.doi.org/10.1089/aid.2015.0381

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5067863/
https://www.ncbi.nlm.nih.gov/pubmed/27316778
http://dx.doi.org/10.1089/aid.2015.0381

Ejemplares similares